Teva aims for 25% of U.S. EpiPen market by 2020

This article was originally published here

Teva updated logoTeva (NYSE:TEVA) expects its generic EpiPen auto-injector to claim 25% of the U.S. market by the end of this year, according to a report from Seeking Alpha.

For years, Mylan‘s (NSDQ:MYL) brand-name emergency allergy device has dominated the markets. But the company faced widespread criticism in 2016 when reports revealed that Mylan hiked the price of the EpiPen by nearly 500% since 2007. In response, Mylan launched its own EpiPen generic for roughly $300.

Get the full story at our sister site, Drug Delivery Business News.

The post Teva aims for 25% of U.S. EpiPen market by 2020 appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply